C4 Therapeutics Inc (CCCC)

$2.45 +0.07 (2.94%)
Market Cap 169.39M
Revenue (ttm) 35.58M
Net Income (ttm) -105.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -296.01%
Debt to Equity Ratio 0.00
Volume 1,814,400
Avg Vol 2,086,538
Day's Range N/A - N/A
Shares Out 71.17M
Stochastic %K 55%
Beta 2.94
Analysts Strong Sell
Price Target $11.50

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BR...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 231 0700
Address:
490 Arsenal Way, Suite120, Watertown, United States
josegodoy
josegodoy Oct. 25 at 10:20 AM
$CCCC I can comfortably argue for a $6-$7 price target (PT). After the aforementioned PT is (/if) achieved and (bullishly) digested properly, we can talk about double digits. An opinion
0 · Reply
lelongduzboob
lelongduzboob Oct. 24 at 9:34 PM
$CCCC Bain Capital Life Sciences Fund II, L.P. (991,188 shares), BCIP Life Sciences Associates, LP (120,722 shares), and BCLS II Equity Opportunities, LP (2,020,000 shares plus warrants for 4,040,000 shares).
0 · Reply
zawojak
zawojak Oct. 23 at 9:53 PM
$CCCC just checked small investors on fintel, many are selling recently or reducing positions. I suppose ot is due to waiting time for the next meaningful milestone 2years +. Oh well I will keep holding and adding on dips close to $2. Still very bullish long term
1 · Reply
Andysss
Andysss Oct. 23 at 7:03 PM
$CCCC One really big bite from the tutes
0 · Reply
zawojak
zawojak Oct. 23 at 1:33 PM
$CCCC
0 · Reply
hk042
hk042 Oct. 23 at 11:59 AM
$CCCC Nice dip. Glad i could add at these levels! Very bullish soon!
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 23 at 12:24 AM
$TNXP $IMRX $NUVB $CCCC $ALT five cheap biotechs worth holding long 💪
0 · Reply
ckeiger
ckeiger Oct. 22 at 2:54 PM
$CCCC Does anyone know why this is down so much?
2 · Reply
zawojak
zawojak Oct. 22 at 2:53 PM
$CCCC share count increased by couple M.
0 · Reply
zawojak
zawojak Oct. 22 at 9:46 AM
$CCCC Just added 100
1 · Reply
Latest News on CCCC
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

Oct 16, 2025, 7:08 AM EDT - 9 days ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Oct 1, 2025, 7:00 AM EDT - 24 days ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

C4 Therapeutics, Inc. - Special Call

Sep 22, 2025, 5:23 AM EDT - 4 weeks ago

C4 Therapeutics, Inc. - Special Call

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 20, 2025, 11:00 AM EDT - 5 weeks ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 4, 2025, 7:00 AM EDT - 7 weeks ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Sep 3, 2025, 7:00 AM EDT - 7 weeks ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:00 AM EDT - 2 months ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

Jun 16, 2025, 1:50 PM EDT - 4 months ago

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 6 months ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 8 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2025, 7:00 AM EST - 8 months ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Dec 8, 2024, 12:30 PM EST - 11 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Jun 10, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 1 year ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Mar 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 22, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 9, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

C4 Therapeutics Announces Chief Financial Officer Succession

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 8, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 15, 2023, 1:58 AM EDT - 2 years ago

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

Jul 5, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

Jun 20, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 30, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 4, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 19, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Feb 23, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

Feb 8, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

Jan 30, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

josegodoy
josegodoy Oct. 25 at 10:20 AM
$CCCC I can comfortably argue for a $6-$7 price target (PT). After the aforementioned PT is (/if) achieved and (bullishly) digested properly, we can talk about double digits. An opinion
0 · Reply
lelongduzboob
lelongduzboob Oct. 24 at 9:34 PM
$CCCC Bain Capital Life Sciences Fund II, L.P. (991,188 shares), BCIP Life Sciences Associates, LP (120,722 shares), and BCLS II Equity Opportunities, LP (2,020,000 shares plus warrants for 4,040,000 shares).
0 · Reply
zawojak
zawojak Oct. 23 at 9:53 PM
$CCCC just checked small investors on fintel, many are selling recently or reducing positions. I suppose ot is due to waiting time for the next meaningful milestone 2years +. Oh well I will keep holding and adding on dips close to $2. Still very bullish long term
1 · Reply
Andysss
Andysss Oct. 23 at 7:03 PM
$CCCC One really big bite from the tutes
0 · Reply
zawojak
zawojak Oct. 23 at 1:33 PM
$CCCC
0 · Reply
hk042
hk042 Oct. 23 at 11:59 AM
$CCCC Nice dip. Glad i could add at these levels! Very bullish soon!
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 23 at 12:24 AM
$TNXP $IMRX $NUVB $CCCC $ALT five cheap biotechs worth holding long 💪
0 · Reply
ckeiger
ckeiger Oct. 22 at 2:54 PM
$CCCC Does anyone know why this is down so much?
2 · Reply
zawojak
zawojak Oct. 22 at 2:53 PM
$CCCC share count increased by couple M.
0 · Reply
zawojak
zawojak Oct. 22 at 9:46 AM
$CCCC Just added 100
1 · Reply
Andysss
Andysss Oct. 22 at 4:49 AM
$CCCC Some corrections. Schedule 13G filed by Point72 on Oct 21 discloses potential ownership of ~22million shares (9.99 % cap). The position includes ≈14.2 M shares underlying warrants — actual exercisable ownership is limited to 9.99 % due to a blocker provision. Worth noting: about 14.2M of those shares are underlying warrants, with a 9.99% blocker. I see this as major bullish signal
2 · Reply
Letsinvest2024
Letsinvest2024 Oct. 21 at 5:08 PM
$RANI I was mad but look at it now Next $CCCC
0 · Reply
LabPsycho
LabPsycho Oct. 21 at 4:34 PM
$PRLD @pchr 1. Several potential upcoming milestones 2. Molecular glues / degraders seem to be regaining traction (i.e. $CCCC decent results and several big pharma collaborations and $GLUE recent huge partnership with Novartis with tons of $$$ (120M $ UPFRONT) 3. $PRLD fusing PROTAC / molecular degraders with antibodies (great idea IMO with some likely specialized applications) 4. CEO purchased shares about a year ago 5. Generally drifting up with many other beat down biotechs. 6. Recent phantom spike up to $1.91 (then full retrace) suggests wind of a (positive?) development a few weeks ago 7. My molecular dynamic simulation posted here a couple weeks ago (strong bias! LoL)
0 · Reply
4Reel
4Reel Oct. 21 at 3:09 PM
$CCCC broke out of the trading range, above all moving averages 3 dollars by end of month imo
0 · Reply
zawojak
zawojak Oct. 21 at 8:57 AM
$CCCC is
0 · Reply
Andysss
Andysss Oct. 21 at 6:17 AM
$CCCC huge news.
1 · Reply
Bruce_Cullen
Bruce_Cullen Oct. 21 at 3:30 AM
$CCCC I'm in... position trader, what should I know about this besides what ive read?
1 · Reply
datapoint1728
datapoint1728 Oct. 21 at 3:11 AM
$CCCC Schedule 13G filed by Steven A. Cohen of Point72 Capital Advisors, Inc. on October 21, 2025 to disclose the ownership of 9.99% of CCCC with 22,647,647 shares. Steven A. Cohen (born June 11, 1956) is an American hedge-fund manager and owner of the New York Mets of Major League Baseball (MLB) since September 14, 2020, owning just over 97% of the team.[3] He is the founder of hedge fund Point72 Asset Management and S.A.C. Capital Advisors.[4]
1 · Reply
vu_jade
vu_jade Oct. 21 at 1:08 AM
$CCCC told you this was a buy months ago
0 · Reply
4Reel
4Reel Oct. 20 at 12:49 PM
$CCCC looks like all the shares was added. Should close the offering. 21.9m shares was the offering at 2.47. I expect them to use the warrants on news related items when volume is present. They have over 300m cash right now including thr costs of this quarter, as last quarter they stated $223M ending june 30.
1 · Reply
Anonymous10000
Anonymous10000 Oct. 19 at 8:44 PM
$CCCC look at $SLS tomorrow. Large gain after hours Friday, but we are just getting started. News Oct. 29.
0 · Reply
zawojak
zawojak Oct. 18 at 9:39 AM
$CCCC Price target decreased by 20% to US$12.00Down from US$15.00, the current price target is an average from 7 analysts. Ref: Simply wall street. I don’t know how hammered a one stock can be. I guess since majority of catalysts news have been shifted to 2028 shorts will have 3 years of scalping here. I have already stopped averaging down my bags inless its below $1.95. I have heavy bags tho.
1 · Reply